Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Lack of Discontinuation of Statin Therapy After Diagnosis of End-Stage Cancer

June 14th 2013

The diagnosis of end-stage cancer rarely led to the clinically indicated discontinuation of statin therapy when prescribed for primary prevention.

Dr. Heinemann Reviews the FIRE-3 Trial Results

June 2nd 2013

Volker Heinemann, MD, PhD, from the University of Munich, discusses results from the phase III FIRE-3 trial that looked at FOLFIRI plus bevacizumab or cetuximab as a first-line treatment for patients with wild-type KRAS metastatic colorectal cancer.

Cetuximab OS Results Top Bevacizumab in mCRC

June 2nd 2013

Frontline cetuximab plus FOLFIRI chemotherapy improved overall survival by 3.7 months versus bevacizumab plus FOLFIRI in patients with KRAS wild-type metastatic colorectal cancer.

Adding Cetuximab to Chemotherapy Increases Resection Rates of Colorectal Liver Metastases and Extends Survival

May 23rd 2013

The addition of cetuximab to chemotherapy as first-line treatment of KRAS wild-type unresectable colorectal liver metastases resulted in a higher rate of resection and longer survival than chemotherapy alone

High Levels of Cardiovascular Fitness Reduces the Risk of Developing and Dying From Cancer

May 15th 2013

Men with a high level of cardiovascular fitness at middle age had a reduced risk of developing and dying from lung and colorectal cancer later in life.

What Is the Role of Maintenance Therapy in Cancer Care?

May 1st 2013

Experts provide an in-depth look at the treatment strategy in patients with solid tumors, specifically looking at the role of maintenance therapy.

Conclusion: Optimal Side Effect Management in CRC

April 2nd 2013

Case Study: Treating Metastatic Colorectal Cancer

April 2nd 2013

Second-Line Therapies for Patients With mCRC

April 2nd 2013

Determining Optimal Treatments in mCRC

April 2nd 2013

Treatment Sequencing in Metastatic Colorectal Cancer

April 2nd 2013

Treating Unresectable Metastatic Colorectal Cancer

April 2nd 2013

Treating Resectable Metastatic Colorectal Cancer

April 2nd 2013

Exploring the Neoadjuvant Treatment of Rectal Cancer

April 2nd 2013

Understanding the Role of Aspirin in Colorectal Cancer

April 2nd 2013

Managing Adjuvant Treatment in Colorectal Cancer, Part II

April 2nd 2013

Managing Adjuvant Treatment in Colorectal Cancer, Part I

April 2nd 2013

Side Effects With Regorafenib Occur Early and Tend to Taper

March 8th 2013

The incidence of adverse effects with regorafenib in metastatic colorectal cancer is highest during the first treatment cycle and then diminishes over time.

Bevacizumab Plus FOLFOXIRI May Offer New First-Line Option in mCRC

March 5th 2013

FOLFOXIRI plus bevacizumab improved progression-free survival and response rates with a modest increase in side effects compared with FOLFIRI plus bevacizumab in patients with unresectable metastatic colorectal cancer.

Dr. Bendell on Hsp90 Inhibition in Advanced Solid Tumors

March 4th 2013

Johanna Bendell, MD, Director of GI Cancer Research Program, Associate Director, Drug Development Program, Sarah Cannon Research Institute, discusses the inhibition of heat shock protein 90 (Hsp90) in advanced solid tumors.